<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260375</url>
  </required_header>
  <id_info>
    <org_study_id>MSC liver transplant tolerance</org_study_id>
    <secondary_id>2014-001531-37</secondary_id>
    <nct_id>NCT02260375</nct_id>
  </id_info>
  <brief_title>MSC Therapy in Liver Transplantation</brief_title>
  <official_title>THIRD-PARTY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVER TRANSPLANT RECIPIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monia Lorini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general aim of the present study is to test a cell therapy with third-party allogeneic
      ex-vivo expanded MSCs as a strategy to induce tolerance in liver transplant recipients. MSCs
      will be prepared accordingly to established protocols , starting from diagnostic samples of
      bone marrow aspirates (2-5 mL) or using the remnants in the bag and filter at the end of the
      bone marrow infusions. From these samples, MSCs will be expanded in GMP approved facilities
      and used for the present study in patients undergoing liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Changes from baseline up to 120 month.</time_frame>
    <description>At each visit overall clinical condition of the patient will be evaluated and any adverse event will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver tissue mRNA level of Transferrin receptor CD71 (TFRC) and Hepcidin antimicrobial peptide (HAMP) genes</measure>
    <time_frame>At 12 and 60 month.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Circulating naive and memory T cell conts (CD45RA/CD45RO)(flow cytometry analysis)</measure>
    <time_frame>Changes from baseline at 6 and 12 months after transplant, then every 6 months till the first 3 years after transplant and then yearly up to 120 month.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T-cell function in mixed lymphocyte reaction</measure>
    <time_frame>Changes from baseline at 6 and 12 months after transplant, then every 6 months till the first 3 years after transplant and then yearly up to 120 month.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>Mesenchymal Stromal Cells (MSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stromal Cells</intervention_name>
    <arm_group_label>Mesenchymal Stromal Cells (MSC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For this study, the following inclusion criteria should be fulfilled before starting
        withdrawal of drugs after 1 year post-transplant:

          -  First liver transplant

          -  Capable of understanding the purpose and risk of the study

          -  Written informed consent

        Exclusion Criteria:

          -  Specific contraindication to MSC infusion

          -  Any clinical relevant condition that might affect study participation and/or study
             results

          -  Pregnant women and nursing mothers

          -  Unwillingness or inability to follow the study protocol in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Remuzzi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norberto Perico, MD</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS-Istituto di Ricerche Farmacologiche M. Negri</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Colledan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Fagiuoli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martino Introna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratorio G.Lanzani, Bergamo, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alessandro Rambaldi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.O. Ospedale Papa Giovanni XXIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Pinna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S. Orsola Bologna, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Velati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico S. Orsola Bologna, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe Remuzzi, MD</last_name>
    <phone>0039 0352674037</phone>
    <email>gremuzzi@hpg23.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.S.C Nefrologia e Dialisi</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Remuzzi, MD</last_name>
      <phone>0039 0352674037</phone>
      <email>gremuzzi@hpg23.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Remuzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Chirurgia Generale III</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Colledan, Md</last_name>
      <phone>00390352674347</phone>
      <email>mcolledan@hpg23.it</email>
    </contact>
    <investigator>
      <last_name>Marco Zambelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Ematologia</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <phone>00390352673684</phone>
      <email>arambaldi@hpg23.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Gastroenterologia</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Fagiuoli, MD</last_name>
      <phone>00390352674259</phone>
      <email>sfagiuoli@hpg23.it</email>
    </contact>
    <investigator>
      <last_name>Giulia Magini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio di Immunoematologia e Medicina Trasfusionale</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Velati, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marina Buzzi, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Claudio Velati, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unit√† Chirurgia Generale e Trapianti</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pinna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Pinna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>Monia Lorini</investigator_full_name>
    <investigator_title>EC Secretary</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stromal cells; liver transplantation; tolerance.</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

